Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Famitinib plus Dalpiciclib and Fulvestrant in Advanced Breast Cancer
NCT05176080Phase 2Terminated
- Sponsor
- Henan Cancer Hospital
- Start
- Dec 2021
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of famitinib in breast cancer, sponsored by Henan Cancer Hospital. Primary endpoints: Recommended Phase 2 Dose up to 4 weeks and Objective Response Rate up to 2 years. Started Dec 2021; status: terminated.
02
Drugs
famitinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05176080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05176080.